Cassava Sciences announces publication on effects of simufilam

Cassava Sciences announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research. The new paper examined the effects of simufilam on mTOR. Simufilam is Cassava Sciences’ novel, oral drug candidate currently in Phase 3 clinical testing in patients with mild-to-moderate Alzheimer’s disease dementia. The scientific literature shows overactive mTOR plays a key role in aging, Alzheimer’s disease and other conditions. When functioning normally, mTOR monitors cellular needs and is activated by insulin. The research published today shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer’s patients versus healthy controls. After oral administration of simufilam 100 mg twice daily to Alzheimer’s patients for 28 days, lymphocytes showed normalized mTOR activity and restored mTOR sensitivity to insulin. An abstract of the research paper appeared on-line June 23, 2023, ahead of print and is titled “Simufilam Suppresses Overactive mTOR and Restores Its Sensitivity to Insulin in Alzheimer’s Disease Patient Lymphocytes”. This paper is open-access under the terms of the Creative Commons Attribution License. The full-text paper is expected to be available on-line shortly.